Union Health Ministry Proposes Revised Microbial Contamination Limits for Sterile Drug Manufacturing

The Union Health Ministry has proposed revising the permissible microbial contamination limits for pharmaceutical manufacturing facilities that produce sterile medicines, including injectable drugs and ophthalmic preparations. The proposed changes are part of an amendment to the Drugs Rules, 1945.

In a draft notification issued last week, the ministry proposed replacing the existing Table 3 under Schedule M. This table specifies the recommended limits for microbial contamination in manufacturing environments designated for sterile products.

The proposed revisions encompass four specific parameters used to monitor the presence of microorganisms in pharmaceutical manufacturing areas: air samples, settle plates, contact plates, and glove prints.

Under the framework, Grade A areas are defined as critical zones where exposed products, containers, and sterilised components are handled. Maintaining strict microbial control in these areas remains essential to safeguarding the quality and safety of sterile pharmaceutical products.

For Grade B areas, the draft notification proposes specific limits including 10 colony-forming units (CFU) per cubic metre of air, five CFU per settle plate over a four-hour period, five CFU per contact plate, and five CFU per glove print.

For Grade C areas, the proposed limits are set at 100 CFU per cubic metre of air, 50 CFU per settle plate, and 25 CFU per contact plate. For Grade D areas, the corresponding limits are 200, 100, and 50 CFU, respectively. CFU is utilized as a measure to estimate the number of viable microorganisms in a sample, with the four grades representing varying cleanliness requirements within sterile manufacturing facilities.

The proposed amendment falls under Schedule M, Part II, Requirement 4, paragraph 4.9 of the Drugs Rules. This section governs the specific requirements for the manufacture of sterile products, covering both small and large volume parenterals along with sterile ophthalmic preparations.

Following the issuance of the Gazette notification, the ministry has invited objections and suggestions from stakeholders and affected persons within a 30-day window. These submissions will be reviewed before the government finalizes the amendment.

Ministry officials stated that the proposed revision aims to align the Revised Schedule M with World Health Organization (WHO) guidelines, thereby strengthening the regulatory framework for sterile pharmaceutical manufacturing in the country. Additionally, the draft provides for treating any microbial growth detected in Grade A areas as a direct trigger for formal investigation, in line with WHO guidance.

"This proposed regulatory update represents a significant alignment with international manufacturing standards, particularly World Health Organization guidelines. For pharmaceutical companies and related enterprises operating in the sterile drug manufacturing space, compliance with these stricter cleanliness and monitoring parameters will require careful review of existing facility protocols. Stakeholders should utilize the 30-day window to evaluate how these changes to Schedule M impact their operations and submit constructive feedback to the ministry." — Dr. Shishir Gupta, Founder & CEO, StartupLanes